Search Results

Semaglutide use in type 2 diabetes patients has been linked to a reduced risk of Alzheimer’s, suggesting new therapeutic possibilities. (Representational Image-Wikimedia Commons)
Pharmacy

Semaglutide Shows Promise in Preventing Alzheimer’s Disease in Patients with Type 2 Diabetes

Ankur Deka
2 min read
Real-world evidence supports repurposing GLP-1 receptor agonists for Alzheimer’s prevention, with semaglutide showing significant benefits
Opioids are responsible for 72% of drug overdose deaths in the United States. (Unsplash)
Medicine

Semaglutide Associated with Lower Opioid Overdose Risk

MBT Desk
2 min read
Semaglutide is also the active component in the diabetes and weight-loss drugs Wegovy and Ozempic
Ozempic and Wegovy are the two brand names of semaglutide that were in demand for type 2 diabetes and, most importantly, obesity. (Representational image: Pixabay)
MedBound Blog

FDA Warns about Risks of Buying Semaglutide without a Prescription

Dr. Siddiqua Parveen, PharmD
4 min read
The medication semaglutide gained popularity during the last year for the treatment of weight loss
Micrograph of Non-Alcoholic Fatty Liver Disease (Wikimedia Commons)
Medicine

Semaglutide Shows Promise in Treating NAFLD (Non-Alcoholic Fatty Liver Disease)

MBT Desk
3 min read
$9 million grant supports new study of utilizing semaglutide for non-alcoholic fatty liver disease.
Semaglutide, a selective long-acting GLP-1 receptor agonist, has gained popularity for its role in obesity management (Wikimedia Commons)
Medicine

Semaglutide and the Hollywood Weight Loss Trend: A Concerning Shortage and Health Risks

Darshana Vinod Rane
2 min read
Semaglutide Shortage & Health Risks: Hollywood's Weight Loss Trend & Impact on Patients Worldwide
There have been issues of suicidal thoughts linked to another class of weight-loss, diabetes drugs, which have hobbled previous attempts by the drug industry to develop lucrative weight-loss drugs. (Wikimedia commons)
Medicine

EU Extends Ozempic Review to Include More Weight-Loss, Diabetes Drugs

MBT Desk
2 min read
EMA began its review on July 3 after Iceland's health regulator flagged the reports of patients thinking about suicide and one case of thoughts of self-harm after use of Novo Nordisk's diabetes drugs.
Read More
logo
Medbound
www.medboundtimes.com